• Syed S Mahmood, Michael G Fradley, Justine V Cohen, Anju Nohria, Kerry L Reynolds, Lucie M Heinzerling, Ryan J Sullivan, Rongras Damrongwatanasuk, Carol L Chen, Dipti Gupta, Michael C Kirchberger, Magid Awadalla, Malek Z O Hassan, Javid J Moslehi, Sachin P Shah, Sarju Ganatra, Paaladinesh Thavendiranathan, Donald P Lawrence, John D Groarke, and Tomas G Neilan.
• Cardiology Division, New York-Presbyterian Hospital, Weill Cornell Medical Center, New York, New York; Cardiac MR PET CT Program, Department of Radiology, Massachusetts General Hospital, Boston, Massachusetts.
• J. Am. Coll. Cardiol. 2018 Apr 24; 71 (16): 1755-1764.

BackgroundMyocarditis is an uncommon, but potentially fatal, toxicity of immune checkpoint inhibitors (ICI). Myocarditis after ICI has not been well characterized.ObjectivesThe authors sought to understand the presentation and clinical course of ICI-associated myocarditis.MethodsAfter observation of sporadic ICI-associated myocarditis cases, the authors created a multicenter registry with 8 sites. From November 2013 to July 2017, there were 35 patients with ICI-associated myocarditis, who were compared to a random sample of 105 ICI-treated patients without myocarditis. Covariates of interest were extracted from medical records including the occurrence of major adverse cardiac events (MACE), defined as the composite of cardiovascular death, cardiogenic shock, cardiac arrest, and hemodynamically significant complete heart block.ResultsThe prevalence of myocarditis was 1.14% with a median time of onset of 34 days after starting ICI (interquartile range: 21 to 75 days). Cases were 65 ± 13 years of age, 29% were female, and 54% had no other immune-related side effects. Relative to controls, combination ICI (34% vs. 2%; p < 0.001) and diabetes (34% vs. 13%; p = 0.01) were more common in cases. Over 102 days (interquartile range: 62 to 214 days) of median follow-up, 16 (46%) developed MACE; 38% of MACE occurred with normal ejection fraction. There was a 4-fold increased risk of MACE with troponin T of ≥1.5 ng/ml (hazard ratio: 4.0; 95% confidence interval: 1.5 to 10.9; p = 0.003). Steroids were administered in 89%, and lower steroids doses were associated with higher residual troponin and higher MACE rates.ConclusionsMyocarditis after ICI therapy may be more common than appreciated, occurs early after starting treatment, has a malignant course, and responds to higher steroid doses.Copyright © 2018 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

28 keywords...

hide…